.png)
.png)
PTSD and Future Shock
Global Health Challenge Ecosystem
Post-Traumatic Stress Disorder (PTSD) and Future Shock present significant challenges within the Global Health Challenge Ecosystem, demanding innovative solutions and comprehensive treatment approaches. PTSD is a mental health condition triggered by experiencing or witnessing traumatic events, often resulting in severe emotional distress and impairment in daily functioning. Future Shock, on the other hand, refers to the psychological disorientation caused by the rapid pace of technological and societal change, leading to feelings of anxiety and uncertainty about the future.
At Deep Knowledge Group we acknowledge the urgency of addressing these critical issues and possess the expertise required to navigate their complexities effectively. Our focus lies in developing advanced strategies and modern clinics equipped to mitigate the impact of PTSD and Future Shock on individuals and society. Our mission is to stem the prevalence of these conditions and minimize their long-term repercussions on mental health and well-being. Leveraging our extensive experience and analytical capabilities in this domain, we are uniquely positioned to pioneer innovative interventions and treatment modalities. We extend an open invitation to investors and partners to join us in our endeavor. Through collaboration and concerted efforts, we can drive meaningful change and pave the way for more effective management of these pressing challenges.
Global Perspective
PTSD and Future Shock are not confined by geographical borders; they are global phenomena with far-reaching implications for individuals, communities, and societies worldwide. While the manifestations of these conditions may vary across cultures and regions, their under lying impact on mental health and well-being transcends national boundaries.
Post-Traumatic Stress Disorder (PTSD) can arise from exposure to traumatic events such as warfare, natural disasters, or interpersonal violence, leaving a lasting imprint. Future Shock, fueled by rapid technological advancements and societal transformations, contributes to a sense of disorientation and anxiety about the uncertainties of tomorrow.
From bustling metropolises to remote rural areas, the effects of PTSD and Future Shock reverberate across diverse populations, affecting people of all ages, backgrounds, and walks of life. These challenges underscore the need for a global perspective in addressing mental health crises.
By fostering international collaboration, learning from best practices from diverse leading experts, we can develop more effective strategies for prevention, intervention, and long-term management of these critical issues.
Through our commitment to advancing knowledge, fostering innovation, and promoting holistic well-being on a global scale, we strive to make meaningful contributions to the collective effort to address PTSD and Future Shock.
Interactive GeoMap Percent of
People affected by PTSD and Future Shock
Source: Longevity Industry Analytics
Mental Health & Lyme Disease:
Exploring Connections
Mental Health and Lyme Disease represent complex intersections within the realm of human health and well-being. While traditionally viewed as distinct conditions, emerging research suggests intricate connections among them. PTSD, often associated with traumatic experiences, manifests in a variety of symptoms including flashbacks, nightmares, and heightened anxiety. Similarly, Mental Health encompasses a broad spectrum of conditions affecting mood, cognition, and behavior, ranging from depression to anxiety disorders.
Lyme Disease is caused by the bacterium Borrelia burgdorferi and transmitted through tick bites. Beyond its physical manifestations, Lyme Disease has been linked to neuropsychiatric symptoms, including mood disturbances, cognitive impairments, and even PTSD-like presentations. Chronic illness, traumatic experiences, and the physiological effects of infection can exacerbate pre-existing mental health conditions or trigger new ones. Additionally, the challenges of navigating a complex healthcare system and managing chronic symptoms can further impact psychological well-being.
1800+
Clinic Trials
400+
Top Clinics
1200+
Investors
20000+
Data Points
Solutions for Global Health Challenges
The Lyme Pandemia with Diabetes, Autism and Alzheimer Diseases, PTSD pose a significant challenge, with a growing pharmaceutical market each year. Despite this expansion, the issue persists, highlighting the complexity and difficulty in finding a comprehensive resolution to the problem. This group of diseases are not effectively addressed solely through standard treatments.
At DKG, we frequently encounter people facing challenges in managing their symptoms even after undergoing conventional therapy. Drawing on over a decade of analytical expertise, we have accumulated and explored advanced holistic methods to effectively impact on the spread of these problems in the World.
Our proficiency in treating such diseases revolves around discerning the coinfections and other complicating factors associated with these ailments. To tackle this distinct set of considerations our specialists employ personalized proprietary treatments that integrate cutting-edge and natural therapies related to Mitochondrial, Space, Restorative, Functional Medicine within the framework of Longevity Medicine.
Hyperbaric Oxygen Therapy
Intermittent Hypoxia–Hyperoxia Training
Plasmapheresis
Intervention
Keto and Carnivorous Diets
PTSD and Future Shock Global Challenge Ecosystem Dashboard
PTSD and Future Shock Global Challenge Ecosystem Dashboard is a centralized hub designed to meet all the market and business intelligence needs of its users. It offers comprehensive support, encompassing benchmarking for companies, technologies, and thorough competitive and SWOT analysis for 1800+ clinical trials, 400+ leading clinics, 1200+ investors, and 20,000+ data inputs within the PTSD and Future Shock sector.
PTSD Market in Charts
Anticipated to undergo significant expansion, the global market for PTSD treatment is poised to grow from USD 29.8 billion in 2021 to USD 45.9 billion in 2032, reflecting a robust Compound Annual Growth Rate (CAGR) of around 4.4%.
The upsurge in healthcare advancements, backed by substantial investments from major corporations and government institutions, underscores the increasing importance of precise diagnostics and refined treatment approaches in addressing the intricacies of PTSD. This extends to providing comprehensive support for individuals across the entire spectrum.
PTSD Patient Logistic Journey Map
Explore the comprehensive journey of PTSD and Future Shock patients through the interactive logistic pathway. Each stage offers a concise overview, and by selecting individual stages, you can delve into detailed descriptions that provide insights into AI-driven diagnostic, treatment, and management processes tailored specifically to there disorders. All buttons on this visualization are interactive, allowing you to click on each one to access detailed information.
Interactive GeoMap PTSD
Clinical Trials
Source: Longevity Industry Analytics
This visualization provides a global overview of clinical trials related to Post-Traumatic Stress Disorder (PTSD). It highlights the diversity and scope of research efforts aimed at understanding and treating PTSD. The trials are distributed across various continents, reflecting a worldwide commitment to addressing this critical mental health issue. Each location on the globe represents a clinical study, showcasing interventions ranging from pharmacological treatments and psychological therapies to innovative technology-based approaches. This map underscores the international efforts to improve treatment outcomes and enhance the quality of life for individuals affected by PTSD.
n the United States, approximately 70% of clinical trials take place, covering a wide range of treatments across various states, including pharmacological, behavioral, and technological interventions. Canada hosts around 5% of trials, focusing on both drug-based and psychotherapeutic methods. The United Kingdom contributes roughly 4% of trials, primarily centered on psychotherapeutic interventions and innovative approaches like virtual reality.
Israel, France, Germany, and Switzerland each host about 2-3% of trials, with focuses ranging from new technologies to psychotherapy. Australia contributes around 2% of trials, exploring both behavioral therapies and pharmacological interventions. Spain hosts approximately 1% of trials, focusing on observational and psychotherapeutic research. Other countries, collectively accounting for about 10% of trials, explore a wide array of PTSD treatments, including traditional drug-based approaches and innovative therapies like mindfulness and neurofeedback.
Strategic Partners Projects
Global Medical Clinics Dashboard
GMC Big Data Analytics Dashboard serves as a one-stop-platform for all market and business intelligence operations its customers may need, including benchmarking for companies, technologies, competitive and SWOT analysis for more than 5000+ medical clinics.
The Dashboard aggregates data from about 12,000+ medicine companies divided into 8 main categories and distributed across various locations. Based on this data, Dashboard provides users with tools for conducting market intelligence, analysing the industry trends and delivering insights from analytics.
Deep Knowledge Group
Projects Platform
End-to-End platform to discover, become involved with, or invest in Deep Knowledge Group’s current scope of market-ready products and projects. Learn about, participate in and invest in Deep Knowledge Group's current portfolio of projects and products that are market-ready.
Longevity.International
Longevity.International is a first-of-its-kind, open-access, non-profit and decentralized Longevity Industry Knowledge and Collaboration platform with the aim of promoting a greater degree of synergy, efficient cooperation, and discussion among a variety of Longevity Industry participants and stakeholders, including companies, investors, non-profits, academic labs and R&D hubs, governmental bodies and policy makers.
AI in BioMed
A comprehensive platform AI in BioMed sheds light on the developing nexus between artificial intelligence and biotechnology. Access to ground-breaking AI frameworks, powerful investors, business leaders, well-known organizations, and state-of-the-art research facilities are all available through this complex center, which addresses a range of subjects from biomarkers and drug discovery to neurotech and space medicine.
Longevity Industry Analytics – Powered by Deep Knowledge Group
Longevity Industry Analytics is a subsidiary of Deep Knowledge Group, a data-driven consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, BioTech, Pharma, FinTech, GovTech, SpaceTech, FemTech, Data Science, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, consulting, media, philanthropy and more.
.png)
